Don't Let The Elite Get Away With Gaslighting That They Didn't Know About Biden's Senility

 by Andrew Korybko via substack,

Biden’s disastrous debate performance last week made it impossible to deny his senility, yet the Western elite is gaslighting they were supposedly oblivious to this until now. Time Magazine published a piece titled “Inside Biden’s Debate Disaster and the Scramble to Quell Democratic Panic”, which was complemented by CNN’s about how “Foreign diplomats react with horror to Biden’s dismal debate performance”.

Both make it seem like Biden’s senility is a surprise for everyone who knew him.

The reality is that they knew about this all along but covered it up by lying that any claims to this effect were “Russian propaganda” and/or a “conspiracy theory”, all because they actually approved of the Democrats installing a literal placeholder in the White House who the liberal-globalist elite could control. It was a refreshing change of pace from Trump, who was much too independent for their liking despite his occasional capitulations to their demands, and it also reassured America’s allies who disliked him too.

They both went along with the lie that Biden is in tip-top mental condition for reasons of political convenience, but now it’s impossible to keep up the charade any longer, hence why they’re all feigning surprise and shock. The elite shouldn’t be allowed to get away with their latest gaslighting and should be exposed for one of the greatest cover-ups in American history. The country is being ruled by a shadowy network of transnational and domestic elites that are united by their radical liberal-globalist ideology.

Biden was chosen as the Democrats’ candidate in 2020 precisely because he was already senile and therefore completely controllable. That party, which functions as the public face of the abovementioned elite network, wanted someone who’d do whatever they demanded on the home and foreign policy fronts. In particular, they sought to turn America into a liberal-globalist hellhole while ramping up NATO’s containment of Russia in Ukraine, but the second policy backfired after the special operation began.

Nevertheless, they’ll never have another chance to install someone like Biden since 2020 was an exceptional election year due to it being a referendum on Trump – who a significant share of the public was preconditioned to falsely believe is the new Hitler – and mail-in voting due to COVID-19. These conditions can never be replicated in the same way again no matter how hard the elite try, which is why they decided to keep Biden as their candidate instead of replace him early on.

Although there’s now a push by some for him to be replaced during the party’s upcoming national convention, Politico and NBC News among others both pointed out that this would be a difficult process, so there’s no guarantee that they’ll seriously attempt it. That said, he might also suffer some sort of emergency that incapacitates him more than he already is, so the scenario can’t be ruled out. In that case, they’ll still do everything they can to gaslight that they had no idea that he was so unhealthy.

Any acknowledgement that they were aware of this would expose their role in 2020’s de facto coup, which was the elite’s latest after the ones in 2001, 1974, and 1963. Back then, 9/11 was exploited as the pretext for taking the national security state to its next level, while Nixon’s resignation in the face of the CIA’s Watergate scandal was meant to remove a truly independent and popular visionary leader. As for Kennedy’s assassination, many believe that it was aimed to stop his planned withdrawal from Vietnam.

The elite’s latest coup was meant to turbocharge the US’ preexisting liberal-globalist trajectory after Trump partially offset it with his comparatively more conservative-nationalist policies, which necessitated provoking a proxy war with Russia in order to unify the West around this ideological cause. The damage has already been dealt and a lot of it is irreparable, but Trump’s return to power would still be better for Americans and the rest of the world, which is why the elite are dead-set against it.  

Irrespective of whether the decision is made to replace Biden, which has its pros such as putting a more publicly appealing candidate on the ballot but also its cons like stoking panic about the party’s electoral prospects, the elite will do everything to cover up for their knowledge of his senility. Acknowledging that they knew about this would leave little doubt in the minds of many that the 2020 election was actually the elite’s latest coup, which his why they’re going overboard gaslighting about how they’re surprised.  

https://www.zerohedge.com/political/dont-let-elite-get-away-gaslighting-they-didnt-know-about-bidens-senility

Pentagon Exposes Biden Lie That Troop Deaths Haven't Occurred Under His Watch

 The Pentagon is trying to run cover following Biden's Thursday night debate falsehood claiming that he is the "only" president this century who hasn't overseen American troop deaths "anywhere in the world". But journalists forced a belated response.

Here's what Biden asserted in the CNN debate with Trump: "The truth is, I'm the only president this century that doesn't have any this — this decade, that doesn't have any troops dying anywhere in the world, like [Trump] did." But the reality is...

Newsmax and others have pointed out that all of the following happened under Biden, some which is relatively recent: 

There have been 16 U.S. troops killed overseas since Biden took office, with 13 during the retreat from Afghanistan on Aug. 26, 2021, and three just five months ago in Jordan. Biden also glossed over the large number of U.S. troops that have perished in training incidents during his time in office.

In April 2023, nine soldiers were killed during a training exercise in Kentucky and 20 U.S. service members have been killed in Osprey-related crashed alone from March 2022 through November 2023, as noted by NBC News.

The Pentagon press secretary was asked about the discrepancy in a Friday press briefing, and whether she stands by the president's statement...

"Thank you for the question. For more on the president's comments and on the debate itself, I'd refer you to the White House," spokesperson Sabrina Singh said, trying to deflect the question.

"But in terms of our service members who have been killed in some tragic events around the world … you've seen the president call these families to express condolences. This is someone that has intimately experienced the commitment and dedication of what our military does," she added.

Singh was asked the same question a second time after the attempted dodge:

"Just to be clear, was the president's statement incorrect?"

"Again, not trying to get involved in that," Singh said.

A journalist pressed her for the third time: "Has President Biden had service members die anywhere in the world during his time in office?"

To which she reluctantly responded: "As you have reported on, we have certainly had service members pass during this administration, and you've seen not just the secretary, but the president, weigh in and comment and offer condolences," Singh finally admitted. She clearly tried to initially desperately avoid contradicting Biden's claim, but the truth proved too obvious in the end.

Does Biden himself even remember what he tried to claim in the Thursday night debate? 

https://www.zerohedge.com/military/pentagon-exposes-biden-lie-troop-deaths-havent-occurred-under-his-watch

He's Just Sundowning: Biden Admin Spins Debate Meltdown - While Family 'Oligarchy' Decides Fate

 How bad must those Hur tapes be?

Following President Joe Biden's disastrous debate performance on Thursday, the world saw that his cognitive decline isn't some right-wing conspiracy theory fueled by "cheapfakes" - and that the White House's desperate attempts to cover for Biden's obvious dementia were nothing more than propaganda.

It's so bad that the NY Times Editorial Board has called for Biden to quit the 2024 race.

It's so bad that the White House is now telling Axios that Biden is 'dependably engaged' between the hours of 10am to 4pm, and that outside of that range, he's 'more likely to have verbal miscues and become fatigued.'

In other words: he's sundowning hard.

Which would explain why he looked like he swapped out Hunter's Finest for his morning sugar at a mid-day rally on Friday, with no hint of a 'cold' we've been told explains his debate performance.

Yet, Biden will tune out calls to exit the race unless his 'kitchen cabinet' of lifelong family advisors counsels him to do so, Axios also reports.

Dave Smith explains during his debate recap:

According to Axios, "The only way President Biden steps aside, despite his debate debacle, is if the same small group of lifelong loyalists who enabled his run suddenly — and shockingly — decides it's time for him to call it quits."

Dr. Jill Biden; his younger sister, Valerie Biden; and 85-year-old Ted Kaufman, the president's longtime friend and constant adviser — plus a small band of White House advisers — are the only Biden deciders.

...

This decades-long kitchen cabinet operates as an extended family, council of elders and governing oligarchy. These allies alone hold sway over decisions big and small in Biden's life and presidency.

• The president engaged in no organized process outside his family in deciding to run for a second term, the N.Y. Times' Peter Baker reports.
• Then Biden alone made the decision, people close to him tell us.

According to the report, if Biden refuses to quit - it's because "He and the oligarchy believe he has a much better chance of being former President Trump than Vice President Harris does."

Additionally, Axios also notes that:

• Biden allies have played out the scenarios and see little chance of anyone besides Harris winning the nomination if he stepped aside.
• Is the Democratic Party going to deny the nomination to the first woman, the first Black American, and the first South Asian American to be elected V.P.? Hard to see.
• These allies privately think Harris would struggle to pull moderate and swing voters, and would enhance Trump's chances. (Harris "fares only one or two points worse than Biden in polls with margins of sampling error that are much larger than that," The Washington Post found.)

Meanwhile, Democratic congressional leaders are receiving panicked calls and texts from colleagues who think Biden's weakness could also cost the party House and Senate seats in November.

"This is no longer about Joe Biden's family or his emotions," said one adviser who's in 'constant touch' with the West Wing. "This is about our country. It's an utter f***ing disaster that has to be addressed."

https://www.zerohedge.com/political/hes-just-sundowning-biden-admin-spins-debate-meltdown-while-family-oligarchy-decides-fate

US Professor Charged With Manipulating Data for Alzheimer’s Drug Trial

 A U.S. medical professor has been charged with fraud for allegedly submitting false data to get millions of dollars in public funds for research into a drug to treat Alzheimer’s disease. 

Federal prosecutors said on Friday that Hoau-Yan Wang, 67, fabricated data included in grant applications to the National Institutes of Health on behalf of himself and a publicly-listed Austin, Texas-based pharmaceutical company for which he was a consultant. 

The NIH awarded Wang, a professor at the City University of New York’s (CUNY) medical school, around $16 million between 2017 and 2021, prosecutors said. 

Prosecutors did not name the company, but it fits the description of Cassava Sciences, which lists Wang as a consultant. Cassava was not accused of wrongdoing. 

In 2021, two physicians unaffiliated with Cassava alleged the research underpinning its Alzheimer's drug, called simufilam, was based on manipulated and misrepresented data. 

Wang did not immediately respond to a request for comment.

A spokesperson for CUNY said the university "has and will continue to cooperate to the fullest degree" with the investigation. A NIH spokesperson said the institute takes research misconduct very seriously.

Cassava said in a statement that Wang worked on the drug's "early development" but "had no involvement in the company's phase 3 trials of simufilam."

A phase 3 trial refers to a late-stage, large-scale test. The company said on May 10 that over 735 patients had participated in simufilam's phase 3 trial. 

A lawyer for Cassava told Reuters in 2022 that allegations about simufilam's research were "false and misleading," and that the company had complied with requests for information from government agencies. 

Cassava's website describes Wang as the co-lead scientist on discovery and development of simufilam. Slides of conference presentations available on Cassava's website refer to Wang as a consultant to the company.. 

Cassava shares surged from $7 in January 2021 to above $135 in July 2021 on investor hopes the company was on the verge of a breakthrough in treating Alzheimer's, a common form of dementia. 

The stock plunged after its research results were questioned. Shares were down more than 40% at $11 on Friday afternoon.

Wang could face decades in prison if convicted on all four counts of fraud and false statements he faces, though any sentence would ultimately be determined by a judge. A federal grand jury sitting in Greenbelt, Maryland, indicted him on Thursday, court records showed.  

https://www.usnews.com/news/top-news/articles/2024-06-28/us-professor-charged-with-manipulating-data-for-alzheimers-drug-trial

Now for the sitdown: Obama, Klain and Biden meet to discuss replacement, Kamala becomes Fredo

 By Monica Showalter

Like mafiosos, or the old gray men of the Kremlin trying to figure out how to get rid of Leonid Brezhnev or Konstantin Chernenko, Democrat power players have called in Joe Biden for a sitdown.

Dougie Kass, a hedge fund shark who leads Seabreeze Capital Partners of Palm Beach, Florida, reports the dirt:

 

 

He's echoed by MSNBC's Nicolle Wallace who says roughly the same thing. Kass, being a hedge fund guy, thrives on getting and acting on information before the herd stampedes, so he may well know what's going on. It wouldn't be surprising if Wallace, a consumate political operative and dirty trickster herself, might have some kind of inside track, too:

 

For those of us who have been wondering who pulls the puppet strings, now we have the answer -- Obama, and former chief of staff Ron Klain, who's got 'political operative' written all over him.

Since the meeting is supposedly going on around now, one can just imagine how that may go -- with Biden bitter and resentful at Godfather Obama's smooth manner, knack for words, two terms, and continued popularity, while Biden himself has none of those gifts. Now he's being told by Obama to step down because disaster is going to be what he gets if he doesn't. Klain the consigliere will be there to suggest muscle. Jill Biden, happy to play the role of Mrs. Wilson, and fond of the perks and travel she gets as first lady, will fight back hard. Joe will stare off into space, losing his train of thought.

And more laughable still, as Obama, and Klain discuss replacing Biden with Michigan Gov. Gretchen Whitmer, or California Gov. Gavin Newsom, no doubt offering up sweeteners -- business deals, immunity from prosecution for corruption -- and warn him Trump will throw him in jail if he wins, so he best save himself, outside the room, Vice President Kamala Harris will be fuming. Hadn't she served her role? Hadn't she done what she was told? They will treat her like Fredo as she pleads her case, thanks but no thanks. Perhaps she may be offered the California governor's slot in exchange for her cooperation. If she doesn't cooperate, she gets nothing. An offer she can't refuse. 

While Democrats are hardly sticklers for following their own laws and rules, there could be a few poison pills lying around:

 

 

After all, any Republican worth his or her salt would want to make sure the Democrats keep Biden at the top of the ticket.

Maybe they'll get even more mafia-like and arrange an 'accident.' But most likely, they will just let it get ugly and word will leak out to the press.

Wouldn't that be a pretty picture? Doesn't sound like a recipe for success for the Democrats as the walls come crashing down around them.

Let's get out the popcorn.

https://www.americanthinker.com/blog/2024/06/now_for_the_sitdown_obama_klain_and_biden_meet_to_discuss_replacement_kamala_becomes_fredo_report.html

'Is Semaglutide Anti-inflammatory?'

 The anti-obesity drug semaglutide is associated with significant reductions in the inflammatory marker high-sensitivity C-reactive protein (CRP), even in patients who do not lose substantial amounts of weight with the drug, according to data from the SELECT clinical trial.

The research, presented at the European Atherosclerosis Society 2024, involved over 17,600 patients with overweight or obesity and had established cardiovascular disease but not diabetes.

Those given semaglutide experienced a 38% reduction in high-sensitivity CRP levels compared with placebo regardless of baseline body mass index, statin use, cholesterol levels, and other measures.

"Weight loss was associated with greater high-sensitivity CRP reduction in both treatment groups," said study presenter Jorge Plutzky, MD, director of Preventive Cardiology at Brigham and Women's Hospital, Boston, Massachusetts, but "with increased high-sensitivity CRP reductions in those receiving semaglutide."

The drug also "significantly reduced high-sensitivity CRP early," he said, "prior to major weight loss and in those who did not lose significant amounts of weight." The reductions reached approximately 12% at 4 weeks and around 20% at 8 weeks, when the weight loss "was still quite modest," at 2% and 3% of body weight, respectively. Even among patients who achieved weight loss of less than 2% body weight, semaglutide was associated with a reduction in high-sensitivity CRP levels.

In the SELECT trial, semaglutide also resulted in a consistent reduction of around 20% vs placebo in major adverse cardiovascular events such as cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke.

But Naveed Sattar, MD, PhD, professor of cardiometabolic medicine at the University of Glasgow, Scotland, United Kingdom, said in an interview that body weight "is probably the major driver" of CRP levels in the population, accounting for between 20% and 30% of the variation.

Sattar, who was not involved in the study, said that because drugs like semaglutide lower weight but also have anti-inflammatory effects, the question becomes: "Could the anti-inflammatory effects be part of the mechanisms by which these drugs affect the risk of major adverse cardiovascular events?"

Reducing Cardiovascular Events

The current analysis, however, cannot answer the question, he said. "All it tells us is about associations."

"What we do know is semaglutide, predominantly by lowering weight, is lowering CRP levels and equally, we know that when you lose weight, you improve blood pressure, you improve lipids, and you reduce the risk of diabetes," he said.

Sattar also took issue with the researchers' conclusion that the high-sensitivity CRP reductions seen in SELECT occurred prior to major weight loss because the "pattern of CRP reduction and weight reduction is almost identical."

Sattar also pointed out in a recent editorial that the drug appears to have a direct effect on blood vessels and the heart, which may lead to improvements in systemic inflammation. Consequently, he said, any assertion that semaglutide is genuinely anti-inflammatory is, at this stage, "speculation."

Plutzky said that "systemic, chronic inflammation is implicated as a potential mechanism and therapeutic target in atherosclerosis and major adverse cardiovascular events, as well as obesity," and high-sensitivity CRP levels are an "established biomarker of inflammation and have been shown to predict cardiovascular risk."

However, the relationship between high-sensitivity CRP, responses to glucagon-like peptide 1 receptor agonists like semaglutide, and cardiovascular outcomes in obesity "remains incompletely understood," said Plutzky.

https://www.medscape.com/viewarticle/semaglutide-anti-inflammatory-2024a1000c4l

Revised Criteria for Alzheimer's Diagnosis, Staging Released

 A work group convened by the Alzheimer's Association has released revised biology-based criteria for the diagnosis and staging of Alzheimer's disease (AD), including a new biomarker classification system that incorporates fluid and imaging biomarkers as well as an updated disease staging system. 

"Plasma markers are here now, and it's very important to incorporate them into the criteria for diagnosis," senior author Maria C. Carrillo, PhD, Alzheimer's Association chief science officer and medical affairs lead, told Medscape Medical News. 

The revised criteria are the first updates since 2018.

"Defining diseases biologically, rather than based on syndromic presentation, has long been standard in many areas of medicine — including cancer, heart disease and diabetes — and is becoming a unifying concept common to all neurodegenerative diseases," lead author Clifford Jack, Jr, MD, with Mayo Clinic, Rochester, Minnesota, said in a news release from the Alzheimer's Association. 

"These updates to the diagnostic criteria are needed now because we know more about the underlying biology of Alzheimer's and we are able to measure those changes," Jack added. 

The 2024 revised criteria for diagnosis and staging of AD were published online on June 28 in Alzheimer's & Dementia. 

Core Biomarkers Defined

The revised criteria define AD as a biologic process that begins with the appearance of AD neuropathologic change (ADNPC) in the absence of symptoms. Progression of the neuropathologic burden leads to the later appearance and progression of clinical symptoms.

The work group organized AD biomarkers into three broad categories: (1) core biomarkers of ADNPC, (2) nonspecific biomarkers that are important in AD but are also involved in other brain diseases, and (3) biomarkers of diseases or conditions that commonly coexist with AD.

Core Alzheimer's biomarkers are subdivided into Core 1 and Core 2. 

Core 1 biomarkers become abnormal early in the disease course and directly measure either amyloid plaques or phosphorylated tau (p-tau). They include amyloid PET; cerebrospinal fluid (CSF) amyloid beta 42/40 ratio, CSF p-tau181/amyloid beta 42 ratio, and CSF total (t)-tau/amyloid beta 42 ratio; and "accurate" plasma biomarkers, such as p-tau217. 

"An abnormal Core 1 biomarker result is sufficient to establish a diagnosis of AD and to inform clinical decision making [sic] throughout the disease continuum," the work group wrote. 

Core 2 biomarkers become abnormal later in the disease process and are more closely linked with the onset of symptoms. Core 2 biomarkers include tau PET and certain soluble tau fragments associated with tau proteinopathy (eg, MTBR-tau243) but also pT205 and nonphosphorylated mid-region tau fragments. 

Core 2 biomarkers, when combined with Core 1, may be used to stage biologic disease severity; abnormal Core 2 biomarkers "increase confidence that AD is contributing to symptoms," the work group noted. 

The revised criteria give clinicians "the flexibility to use plasma or PET scans or CSF," Carrillo told Medscape Medical News. "They will have several tools that they can choose from and offer this variety of tools to their patients. We need different tools for different individuals. There will be differences in coverage and access to these diagnostics." 

The revised criteria also include an integrated biologic and clinical staging scheme that acknowledges the fact that common co-pathologies, cognitive reserve, and resistance may modify relationships between clinical and biologic AD stages. 

Formal Guidelines to Come 

The work group noted that currently, the clinical use of AD biomarkers is intended for the evaluation of symptomatic patients, not cognitively unimpaired individuals.

Disease-targeted therapies have not yet been approved for cognitively unimpaired individuals. For this reason, the work group currently recommends against diagnostic testing in cognitively unimpaired individuals outside the context of observational or therapeutic research studies. 

This recommendation would change in the future if disease-targeted therapies that are currently being evaluated in trials demonstrate a benefit in preventing cognitive decline and are approved for use in preclinical AD, they wrote. 

They emphasize that the revised criteria are not intended to provide step-by-step clinical practice guidelines for clinicians. Rather, they provide general principles to inform diagnosis and staging of AD that reflect current science.

"This is just the beginning," said Carrillo. "This is a gathering of the evidence to date and putting it in one place so we can have a consensus and actually a way to test it and make it better as we add new science."

This also serves as a "springboard" for the Alzheimer's Association to create formal clinical guidelines. "That will come, hopefully, over the next 12 months. We'll be working on it, and we hope to have that in 2025," Carrillo said. 

The revised criteria also emphasize the role of the clinician. 

"The biologically based diagnosis of Alzheimer's disease is meant to assist, rather than supplant, the clinical evaluation of individuals with cognitive impairment," the work group wrote in a related commentary published online on June 28 in Nature Medicine. 

Recent diagnostics and therapeutic developments "herald a virtuous cycle in which improvements in diagnostic methods enable more sophisticated treatment approaches, which in turn steer advances in diagnostic methods," they continued. "An unchanging principle, however, is that effective treatment will always rely on the ability to diagnose and stage the biology driving the disease process."

Funding for this research was provided by the National Institutes of Health, Alexander family professorship, GHR Foundation, Alzheimer's Association, Veterans Administration, Life Molecular Imaging, Michael J. Fox Foundation for Parkinson's Research, Avid Radiopharmaceuticals, Eli Lilly, Gates Foundation, Biogen, C2N Diagnostics, Eisai, Fujirebio, GE Healthcare, Roche, National Institute on Aging, Roche/Genentech, BrightFocus Foundation, Hoffmann-La Roche, Novo Nordisk, Toyama, National MS Society, Alzheimer Drug Discovery Foundation, and others. A complete list of donors and disclosures is included in the original article. 

https://www.medscape.com/viewarticle/revised-criteria-alzheimers-diagnosis-staging-released-2024a1000c4g